Toronto, ON – Dr John Esdaile, MD, MPH, FRCPC, has been appointed scientific director and CEO of the Canadian Arthritis Network.
Dr Esdaile has been active with the Canadian Arthritis Network since its inception and had a role in creating the Arthritis Research Centre of Canada (ARC). In 2005, he was recognized for his research contributions by his peers, when he received the distinguished investigator award from the Canadian Rheumatology Association.
Dr Esdaile has authored more than 150 publications in refereed journals, as well as more than two dozen publications, books and book chapters. He is recognized for his publication of the efficacy of hydroxychloroquine in systemic lupus erythematosus as his work has altered the treatment of this disease for many patients. Osteoarthritis and rheumatoid arthritis round out his areas of research interest.
He currently divides his time between ARC, teaching at the University of British Columbia (UBC), holding the position of head of the division of rheumatology at UBC, and conducting research into arthritis.
“John Esdaile was a natural choice to lead CAN,” says Dr Robin Armstrong, chair of the Canadian Arthritis Network’s board of directors. “He is a strong leader who has consistently demonstrated his commitment and dedication to the success of CAN.”